Furthermore, a study conducted by Poteti et al. have already described the effect of glutaminase inhibition in the setting of CML and confirmed the potential therapeutic effect of this latter (Poteti et al. 2021). This evidence concerns the gene GLS and chronic myelogenous leukemia, BCR-ABL1 positive.